Canary Stat Heredit™
Focused Hereditary Panel
The Canary Stat Heredit™ Focused Hereditary Panel test identifies genetic mutations for cancer risk, enabling early detection, personalized prevention, tailored treatments, family risk assessment, and eligibility for targeted therapies.
- Cancer Types
- Turnaround Time14 days from the time the sample is received
- Sample TypesPeripheral Blood, Saliva, Buccal Swab
Test Features
Comprehensive Analysis
93 genes + 47 other
Cancer genes + 76 PGx + 17 Intronic Fusions
Compare with other companies
Comprehensive comparison of Canary diagnostic solutions with other companies' offerings
| Test Results | Canary Acuity™ | Canary Pulse™ | Top U.S. and Indian Competitors |
|---|---|---|---|
| Number of Genes Analyzed via NGS | 1091 (+637 Variants) | 468 (+37 Variants) | 300-500 |
| Therapeutic SNVs and InDels | ✓ | ✓ | ✓ |
| Amplifications and Deletions | ✓ | ✓ | ✓ |
| Fusions Genes | ✓ | ✓ | ✓ |
| Tumor Mutational Burden (TMB) | ✓ | ✓ | ✓ |
| Microsatellite Instability (MSI) | ✓ | ✓ | ✓ |
| Homologous Recombination Deficiency (HRD) | ✓ | ✓ | ✓ |
| Loss of Heterozygosity (LOH) | ✓ | ✓ | ✓ |
| Comprehensive Proprietary Database of FDA Approved/Clinical Trial Drugs for Corresponding Biomarkers | ✓ | ✓ | ✓ |
| Depiction of Cancer-Relevant Pathways | ✓ | ✓ | ✗ |
| Germline Variants Affecting Drug Metabolism | ✓ | ✓ | ✗ |
| Complete ACMG Oncology Germline Mutational Analysis | ✓ | ✓ | ✗ |
| In Development | |||
| TCR Clonality | ✓ | ✗ | ✗ |
| HLA Typing | ✓ | ✓ | ✗ |
Compare with Canary Tests
Comprehensive comparison of Canary diagnostic solutions
| Test Results | Canary Acuity™ | Canary Pulse™ | Canary Focus™ |
|---|---|---|---|
| Number of Genes Analyzed via NGS | 1091 (+637 Variants) | 468 (+37 Variants) | 115+ |
| Therapeutic SNVs and InDels | ✓ | ✓ | ✓ |
| Amplifications and Deletions | ✓ | ✓ | ✓ |
| Fusions Genes | ✓ | ✓ | ✓ |
| Tumor Mutational Burden (TMB) | ✓ | ✓ | ✗ |
| Microsatellite Instability (MSI) | ✓ | ✓ | ✓ |
| Homologous Recombination Deficiency (HRD) | ✓ | ✓ | ✗ |
| Loss of Heterozygosity (LOH) | ✓ | ✓ | ✓ |
| Comprehensive Proprietary Database of FDA Approved/Clinical Trial Drugs for Corresponding Biomarkers | ✓ | ✓ | ✓ |
| Depiction of Cancer-Relevant Pathways | ✓ | ✓ | ✗ |
| Germline Variants Affecting Drug Metabolism | ✓ | ✓ | ✗ |
| Complete ACMG Oncology Germline Mutational Analysis | ✓ | ✓ | ✗ |